The U.S. Meals and Drug Administration has accredited a self-injection model of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the remedy of grownup sufferers with generalized myasthenia gravis (gMG) who’re anti-acetylcholine receptor antibody-positive and grownup sufferers with power inflammatory demyelinating polyneuropathy (CIDP).
The Vyvgart Hytrulo prefilled syringe is accredited as a 20- to 30-second subcutaneous injection administered by a affected person, caregiver, or well being care skilled.
The approval is predicated on research evaluating the bioequivalence of the Vyvgart Hytrulo prefilled syringe to Vyvgart Hytrulo in a vial. Human elements validation research moreover confirmed that individuals with gMG or CIDP, or their caregivers, may safely and efficiently put together and administer Vyvgart Hytrulo with the prefilled syringe.
“Today’s FDA approval provides a new self-injection option across both approved indications in the U.S. that is designed for patients who seek more independence with their treatment,” stated Luc Truyen, M.D., Ph.D., the chief medical officer at argenx, in a press release. “Whether patients prefer to receive their treatment in a physician’s office, at home, or while traveling, they can experience treatment on their own terms and continue to benefit from Vyvgart Hytrulo’s favorable safety profile and strong efficacy.”
Approval of self-injectable Vyvgart Hytrulo was granted to argenx.
Extra data:
Extra Info
2025 HealthDay. All rights reserved.
Quotation:
FDA approves self-injection of Vyvgart Hytrulo (2025, April 16)
retrieved 16 April 2025
from https://medicalxpress.com/information/2025-04-fda-vyvgart-hytrulo.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
